Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

IOBT

IO Biotech Inc

Dec 13 • 04:00PM ET

0.8100

Dollar change +0.0182
Percentage change 2.30	%

Healthcare • Biotechnology • Denmark • NASD

Peers: ARGX FATE CARA APLS AFMD KURA ANAB ALLK ALXO CTMX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.37	Insider Own	31.89%	Shs Outstand	65.88M	Perf Week	-5.81%
Market Cap	54.59M	Forward P/E	-	EPS next Y	-1.25	Insider Trans	-0.36%	Shs Float	44.87M	Perf Month	-16.50%
Income	-90.34M	PEG	-	EPS next Q	-0.39	Inst Own	41.67%	Short Float	0.10%	Perf Quarter	4.49%
Sales	0.00M	P/S	-	EPS this Y	31.62%	Inst Trans	-18.31%	Short Ratio	0.08	Perf Half Y	-38.17%
Book/sh	1.10	P/B	0.74	EPS next Y	7.53%	ROA	-68.83%	Short Interest	0.05M	Perf Year	-34.08%
Cash/sh	1.19	P/C	0.68	EPS next 5Y	-	ROE	-78.50%	52W Range	0.66 - 2.10	Perf YTD	-56.91%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-46.06%	ROI	-122.26%	52W High	-61.39%	Beta	0.28
Dividend TTM	-	Quick Ratio	5.37	Sales past 5Y	0.00%	Gross Margin	-	52W Low	22.73%	ATR (14)	0.09
Dividend Ex-Date	-	Current Ratio	5.37	EPS Y/Y TTM	44.14%	Oper. Margin	-	RSI (14)	41.62	Volatility	8.10% 12.32%
Employees	68	Debt/Eq	0.03	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.33	Target Price	8.20
Option/Short	No / Yes	LT Debt/Eq	0.02	EPS Q/Q	15.64%	Payout	-	Rel Volume	0.31	Prev Close	0.79
Sales Surprise	-	EPS Surprise	-25.22%	Sales Q/Q	-	Earnings	Nov 12 BMO	Avg Volume	553.53K	Price	0.81
SMA20	-1.51%	SMA50	-20.76%	SMA200	-36.90%	Trades		Volume	170,380	Change	2.30%

Nov-12-24 07:05AM	IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights (GlobeNewswire) -11.68%
Nov-11-24 04:05PM	IO Biotech Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Nov-07-24 10:00AM	IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study (GlobeNewswire) +6.03%
Oct-04-24 09:00AM	IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting (GlobeNewswire) +13.86%
Sep-14-24 02:30AM	IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer (GlobeNewswire)
06:53AM	Loading…
Sep-02-24 06:53AM	IO Biotechs melanoma treatment trial to continue after IDMC review (Clinical Trials Arena)
Aug-30-24 04:05PM	IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma (GlobeNewswire) -33.33%
Aug-26-24 04:05PM	IO Biotech Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-13-24 07:05AM	IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights (GlobeNewswire) +17.69%
Jul-25-24 04:05PM	IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024 (GlobeNewswire)
Jul-04-24 10:01AM	3 Undervalued Biotech Gems With 200%+ Analyst Price Targets (InvestorPlace)
May-23-24 08:30AM	IO Biotech to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
May-14-24 01:54PM	IOBT Stock Earnings: IO Biotech Beats EPS for Q1 2024 (InvestorPlace)
07:55AM	IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights (GlobeNewswire)
Apr-24-24 04:30PM	IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
08:30AM	Loading…
Apr-15-24 08:30AM	IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness (GlobeNewswire)
Apr-09-24 12:00PM	IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103 (GlobeNewswire)
Apr-05-24 08:30AM	IO Biotech Appoints Faical Miyara, Ph.D., as Chief Business Officer (GlobeNewswire)
08:30AM	IO Biotech Appoints Fai al Miyara, Ph.D., as Chief Business Officer (GlobeNewswire)
Mar-07-24 02:01PM	IO Biotech Inc (IOBT) Reports Year-End Financial Results and Progress in Clinical Trials (GuruFocus.com) +6.63%
Mar-06-24 04:11PM	IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-05-24 10:52PM	IOBT Stock Earnings: IO Biotech Misses EPS for Q4 2023 (InvestorPlace)
04:40PM	IO Biotech Announces 2023 Fourth-Quarter and Year-End Results (GlobeNewswire)
Feb-26-24 04:05PM	IO Biotech to Present at 44th Annual Cowen Health Care Conference (GlobeNewswire)
Dec-21-23 08:30AM	IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial (GlobeNewswire)
Nov-13-23 08:12AM	IO Biotech Announces 2023 Third Quarter Results (GlobeNewswire)
08:00AM	IO Biotech Appoints Helen Collins, MD, to its Board of Directors (GlobeNewswire)
Nov-10-23 08:00AM	IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma (GlobeNewswire)
Nov-08-23 04:30PM	IO Biotech Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Nov-01-23 08:30AM	IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting (GlobeNewswire)
12:30PM	Loading…
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE) +8.38%
Oct-23-23 01:00AM	Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Society for Medical Oncology (ESMO) Congress (GlobeNewswire) -5.05%
Oct-03-23 04:30PM	IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting (GlobeNewswire) +10.22%
Sep-12-23 08:05AM	IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer (GlobeNewswire) -13.20%
Sep-06-23 08:35AM	IO Biotech Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-17-23 08:59AM	10 Best New Penny Stocks to Buy Now (Insider Monkey)
Aug-16-23 09:01PM	Stonepine Capital Management, LLC Acquires New Stake in IO Biotech Inc (GuruFocus.com)
Aug-11-23 08:30AM	IO Biotech Announces 2023 Second Quarter Results (GlobeNewswire)
08:05AM	IO Biotech Appoints Heidi Hunter to its Board of Directors (GlobeNewswire)
Aug-08-23 08:05AM	IO Biotech Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023 (GlobeNewswire)
Aug-07-23 08:30AM	IO Biotech, Inc. Announces $75 Million Private Placement Financing (GlobeNewswire)
Jul-28-23 08:05AM	IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial at University of California Davis Comprehensive Cancer Center (GlobeNewswire)
Jul-25-23 04:05PM	IO Biotech Announces Abstract Accepted for Mini Oral Presentation at IASLC 2023 World Conference on Lung Cancer (GlobeNewswire)
Jul-18-23 04:05PM	IO Biotech Strengthens Executive Management and US Presence with Appointment of Qasim Ahmad, MD, as Chief Medical Officer (GlobeNewswire)
Jun-15-23 09:55AM	2 Strong Buy Penny Stocks That Could Rally Over 300% (TipRanks) +27.33%
08:18AM	IO Biotech (IOBT) Down Despite Positive Update on Melanoma Study (Zacks)
Jun-14-23 12:42PM	Why Are IO Biotech Shares Trading Lower Today (Benzinga) -26.48%
08:00AM	IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone (GlobeNewswire)
Jun-01-23 08:30AM	IO Biotech Appoints Christine Richter, Ph.D., MBA, as Senior Vice President, Commercial and Program Lead (GlobeNewswire)
May-30-23 04:35PM	IO Biotech to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-11-23 04:05PM	IO Biotech Announces 2023 First-Quarter Results (GlobeNewswire) +9.69% -7.91%
May-02-23 07:22AM	Is IO Biotech (NASDAQ:IOBT) In A Good Position To Invest In Growth? (Simply Wall St.)
Mar-22-23 06:14AM	The Chief Financial Officer of IO Biotech, Inc. (NASDAQ:IOBT), Amy Sullivan, Just Bought A Few More Shares (Simply Wall St.)
Mar-14-23 04:11PM	IO Biotech Announces 2022 Fourth-Quarter and Year-End Results (GlobeNewswire) -7.79%
Feb-22-23 07:00AM	IO Biotech to Participate in March 2023 Investor Conferences (GlobeNewswire)
Jan-23-23 08:00AM	IO Biotech Announces Appointment of Devin Smith as General Counsel (GlobeNewswire)
Jan-09-23 07:05AM	IO Biotech Provides Business Update (GlobeNewswire)
Nov-21-22 01:23PM	Analyst Says IO Biotech's Cancer Treatment Approach 'Differentiated' (Benzinga) -12.11%
Nov-09-22 04:07PM	IO Biotech Announces an Invited Oral Presentation and Two Poster Presentations with New Preclinical Data for Additional Pipeline Candidates at the Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting (GlobeNewswire) +16.73%
04:05PM	IO Biotech Announces Third Quarter Results for 2022 (GlobeNewswire)
Nov-03-22 08:00AM	IO Biotech Announces New Clinical Collaboration with Merck to Evaluate Neoadjuvant and Adjuvant IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) in a Phase 2, Multi-cohort Trial in Patients with Resectable Tumors (GlobeNewswire)
Oct-31-22 08:00AM	IO Biotech to Participate in the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-15-22 08:37AM	Is IO Biotech (NASDAQ:IOBT) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Oct-13-22 04:05PM	IO Biotech Announces Appointment of New Chief Financial Officer (GlobeNewswire)
Oct-05-22 08:05AM	IO Biotech Announces Invited Oral Presentation and Two Poster Presentations at the Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting (GlobeNewswire) -6.98%
Sep-06-22 07:30AM	IO Biotech to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference (GlobeNewswire)
Aug-11-22 05:00PM	IO Biotech Announces Second Quarter Results for 2022 (GlobeNewswire)
Jun-06-22 08:00AM	IO Biotech to Participate in the 2022 BIO International Convention (GlobeNewswire) -6.08%
May-26-22 05:00PM	IO Biotech Announces Two Presentations at the American Society of Clinical Oncology Annual Meeting 2022 (GlobeNewswire) -6.19%
May-23-22 08:00AM	IO Biotech to Participate in the Jefferies Healthcare Conference (GlobeNewswire)
May-18-22 07:00AM	IO Biotech Announces Initiation of Phase 3 Combination Trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as First-Line Treatment in Advanced Melanoma (GlobeNewswire) -11.00%
May-16-22 04:15PM	IO Biotech Announces First Quarter Results for 2022 (GlobeNewswire) -8.63% -10.17%
May-08-22 08:07AM	We're Not Very Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Rate (Simply Wall St.)
Apr-22-22 08:33AM	IO Biotech Hosting Key Opinion Leader Webinar Series (GlobeNewswire) +6.62%
Apr-12-22 08:30AM	IO Biotech Announces Initiation of Phase 2 Trial of IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Multi-Arm Basket Trial (GlobeNewswire) -11.69%
Apr-08-22 04:15PM	IO Biotech Announces Presentation of New Data from MM1636 Phase 1/2 Clinical Trial Presented at 2022 AACR Annual Meeting (GlobeNewswire)
Mar-31-22 04:15PM	IO Biotech Announces Year-End Results for 2021 (GlobeNewswire) +6.98%
Mar-08-22 04:30PM	IO Biotech Announces Acceptance of Abstract to be Presented at AACR Annual Meeting on April 8, 2022 (GlobeNewswire)
Mar-04-22 08:00AM	IO Biotech to Present at 42nd Annual Cowen Healthcare Conference (GlobeNewswire)
Mar-03-22 04:05PM	IO Biotech Announces Appointment of David V. Smith to its Board of Directors (GlobeNewswire) -7.40%
Feb-07-22 07:26AM	What Kind Of Investors Own Most Of IO Biotech, Inc. (NASDAQ:IOBT)? (Simply Wall St.)
Jan-21-22 02:30AM	Nasdaqs European Markets Delivered Record Year in 2021 (GlobeNewswire) -7.04%
Dec-09-21 11:05AM	IO Biotech Announces Publication of Phase 1/2 Melanoma Clinical Trial Results in Nature Medicine (GlobeNewswire)
Dec-06-21 08:00AM	IO Biotech Announces Third Clinical Collaboration with Merck to Evaluate IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Phase 2 Multi-Arm Basket Trial (GlobeNewswire) -6.88%
Dec-02-21 03:04PM	Morgan Stanley Predicts Over 100% Rally for These New Strong Buy Stocks (TipRanks) +7.40%
Nov-11-21 08:43AM	4 Stocks Insiders Are Buying (Benzinga)
Nov-09-21 11:06AM	IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Nov-05-21 05:06PM	Real Good Food and 3 More Companies Went Public Friday. Heres How They Did. (Barrons.com)
Nov-04-21 11:52PM	IO Biotech, Inc. Announces Pricing of Initial Public Offering (GlobeNewswire)

IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. Its platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. The company was founded by Mai-Britt Zocca, Inge Marie Svane, and Mads Hald Andersen in December 2014 and is headquartered in Copenhagen, Denmark.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Novo Holdings A/S	Stockholder	Sep 11 '24	Proposed Sale	0.84	1,000,000	844,000		Sep 11 09:04 PM
Novo Holdings A/S	10% Owner	Jul 25 '24	Sale	1.33	51,522	68,339	4,377,927	Jul 26 09:22 PM
Novo Holdings A/S	10% Owner	Jul 26 '24	Sale	1.31	23,478	30,787	4,354,449	Jul 26 09:22 PM
Novo Holdings A/S	10% Owner	May 10 '24	Sale	1.22	658,809	802,495	4,429,449	May 14 09:13 PM
Novo Holdings A/S	10% Owner	Feb 09 '24	Sale	1.50	658,809	988,411	5,088,258	Feb 13 09:31 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IOBT

IO Biotech Inc

Upgrade your FINVIZ experience